Submitted by Anonymous (not verified) on 11 October 2024 - 15:21
Human medicines European public assessment report (EPAR): Qinlock, ripretinib, Date of authorisation: 18/11/2021, Revision: 6, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Qinlock, ripretinib, Date of authorisation: 18/11/2021, Revision: 6, Status: Authorised